Atara Biotherapeutics Inc., a leader in T-cell immunotherapy, has announced the pricing of a $16 million offering involving 834,237 shares of its common stock at $6.61 per share, along with pre-funded warrants to purchase 1,587,108 shares priced at $6.6099 per pre-funded warrant. These securities are being offered to a select group of existing institutional investors, including entities affiliated with Adiumentum Capital Management, EcoR1 Capital, Panacea Venture, and Redmile Group. The gross proceeds from this offering are expected to be $16 million, which Atara plans to use primarily to fund activities required for the biologics license application approval for tab-cel, as well as for working capital and general corporate purposes. TD Cowen is serving as the sole bookrunner for this offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.